Image-guided thermal ablation of hepatocellular carcinoma

Riccardo Lencioni, Laura Crocetti

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is increasingly diagnosed at an early, asymptomatic stage owing to surveillance of high-risk patients. Given the complexity of the disease, multidisciplinary assessment of tumor stage, liver function, and physical status is required for proper therapeutic planning. Patients with early-stage HCC should be considered for any of the available curative therapies, including surgical resection, liver transplantation and percutaneous image-guided ablation. Resection is currently indicated among patients with solitary HCC and extremely well-preserved liver function, who have neither clinically significant portal hypertension nor abnormal bilirubin. Liver transplantation benefits patients who have decompensated cirrhosis and one tumor smaller than 5 cm or up to three nodules smaller than 3 cm, but donor shortage greatly limits its applicability. This difficulty might be overcome by living donation that, however, is still at an early stage of clinical application. Image-guided percutaneous ablation is the best therapeutic choice for nonsurgical patients with early-stage HCC. While ethanol injection has been the seminal percutaneous technique, radiofrequency ablation has emerged as the most effective method for local tumor destruction and is currently used as the primary ablative modality at most institutions.

Original languageEnglish (US)
Pages (from-to)200-207
Number of pages8
JournalCritical Reviews in Oncology/Hematology
Volume66
Issue number3
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Hot Temperature
Liver Transplantation
Ablation Techniques
Neoplasms
Liver
Portal Hypertension
Bilirubin
Fibrosis
Ethanol
Therapeutics
Tissue Donors
Injections

Keywords

  • Hepatocellular carcinoma
  • Image-guided ablation
  • Liver tumor

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Image-guided thermal ablation of hepatocellular carcinoma. / Lencioni, Riccardo; Crocetti, Laura.

In: Critical Reviews in Oncology/Hematology, Vol. 66, No. 3, 06.2008, p. 200-207.

Research output: Contribution to journalArticle

Lencioni, Riccardo ; Crocetti, Laura. / Image-guided thermal ablation of hepatocellular carcinoma. In: Critical Reviews in Oncology/Hematology. 2008 ; Vol. 66, No. 3. pp. 200-207.
@article{84976c2040af404ea77416b95fc0e195,
title = "Image-guided thermal ablation of hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is increasingly diagnosed at an early, asymptomatic stage owing to surveillance of high-risk patients. Given the complexity of the disease, multidisciplinary assessment of tumor stage, liver function, and physical status is required for proper therapeutic planning. Patients with early-stage HCC should be considered for any of the available curative therapies, including surgical resection, liver transplantation and percutaneous image-guided ablation. Resection is currently indicated among patients with solitary HCC and extremely well-preserved liver function, who have neither clinically significant portal hypertension nor abnormal bilirubin. Liver transplantation benefits patients who have decompensated cirrhosis and one tumor smaller than 5 cm or up to three nodules smaller than 3 cm, but donor shortage greatly limits its applicability. This difficulty might be overcome by living donation that, however, is still at an early stage of clinical application. Image-guided percutaneous ablation is the best therapeutic choice for nonsurgical patients with early-stage HCC. While ethanol injection has been the seminal percutaneous technique, radiofrequency ablation has emerged as the most effective method for local tumor destruction and is currently used as the primary ablative modality at most institutions.",
keywords = "Hepatocellular carcinoma, Image-guided ablation, Liver tumor",
author = "Riccardo Lencioni and Laura Crocetti",
year = "2008",
month = "6",
doi = "10.1016/j.critrevonc.2008.01.003",
language = "English (US)",
volume = "66",
pages = "200--207",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Image-guided thermal ablation of hepatocellular carcinoma

AU - Lencioni, Riccardo

AU - Crocetti, Laura

PY - 2008/6

Y1 - 2008/6

N2 - Hepatocellular carcinoma (HCC) is increasingly diagnosed at an early, asymptomatic stage owing to surveillance of high-risk patients. Given the complexity of the disease, multidisciplinary assessment of tumor stage, liver function, and physical status is required for proper therapeutic planning. Patients with early-stage HCC should be considered for any of the available curative therapies, including surgical resection, liver transplantation and percutaneous image-guided ablation. Resection is currently indicated among patients with solitary HCC and extremely well-preserved liver function, who have neither clinically significant portal hypertension nor abnormal bilirubin. Liver transplantation benefits patients who have decompensated cirrhosis and one tumor smaller than 5 cm or up to three nodules smaller than 3 cm, but donor shortage greatly limits its applicability. This difficulty might be overcome by living donation that, however, is still at an early stage of clinical application. Image-guided percutaneous ablation is the best therapeutic choice for nonsurgical patients with early-stage HCC. While ethanol injection has been the seminal percutaneous technique, radiofrequency ablation has emerged as the most effective method for local tumor destruction and is currently used as the primary ablative modality at most institutions.

AB - Hepatocellular carcinoma (HCC) is increasingly diagnosed at an early, asymptomatic stage owing to surveillance of high-risk patients. Given the complexity of the disease, multidisciplinary assessment of tumor stage, liver function, and physical status is required for proper therapeutic planning. Patients with early-stage HCC should be considered for any of the available curative therapies, including surgical resection, liver transplantation and percutaneous image-guided ablation. Resection is currently indicated among patients with solitary HCC and extremely well-preserved liver function, who have neither clinically significant portal hypertension nor abnormal bilirubin. Liver transplantation benefits patients who have decompensated cirrhosis and one tumor smaller than 5 cm or up to three nodules smaller than 3 cm, but donor shortage greatly limits its applicability. This difficulty might be overcome by living donation that, however, is still at an early stage of clinical application. Image-guided percutaneous ablation is the best therapeutic choice for nonsurgical patients with early-stage HCC. While ethanol injection has been the seminal percutaneous technique, radiofrequency ablation has emerged as the most effective method for local tumor destruction and is currently used as the primary ablative modality at most institutions.

KW - Hepatocellular carcinoma

KW - Image-guided ablation

KW - Liver tumor

UR - http://www.scopus.com/inward/record.url?scp=42749093603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749093603&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2008.01.003

DO - 10.1016/j.critrevonc.2008.01.003

M3 - Article

C2 - 18304832

AN - SCOPUS:42749093603

VL - 66

SP - 200

EP - 207

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -